We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Leukocyte Biomarker Applied to Early Detection of Colon Cancer

By LabMedica International staff writers
Posted on 15 Feb 2011
Genetic material extracted from white blood cells can be used as biomarkers for the early detection of colon cancer. More...


The white blood cells, the monocytes, contain genetic material that when analyzed by a novel method, will enhance the monitoring of the development of the colon cancer in patients.

White blood cells play a significant role in the growth of tumors, the metastasis of cancer cells and the formation of blood vessels in and around tumors. In addition, they serve a crucial function in combating malignant cells. They form the core of the defense mechanism, which the body musters against cancer cells. The scientists will link changes in the genetic material of monocytes to the presence and progression of colon cancer. The advantage of this approach is that monocytes are easy to extract from the patient's blood sample.

Massimiliano Mazzone, PhD, who heads a laboratory at the Katholieke Universiteit Leuven (Leuven, Belgium), has just been awarded a substantial grant over a three year period to refine the technique. He has specialized in blood vessel formation in tumors. His most important discovery is the "phalanx cells,” highly streamlined cells on the inside of blood vessels that are needed for improved supply of oxygen. These more quiescent endothelial cell types in nongrowing vessels survive for many years and maintain lumen patency. These cells form a tightly aligned, orderly shaped, smooth layer with a typical cobblestone appearance, comparable to the "phalanx” formation of Greek Spartan soldiers.

The grant was awarded by The Fournier-Majoie Foundation for Innovation (FFMI; Brussels, Belgium). In close collaboration with oncology specialists at the University Hospital of Leuven (Leuven, Belgium), the grant recipients hope to go from the bench to the bedside in a very short time.

Related Links:
Katholieke Universiteit Leuven
The Fournier-Majoie Foundation
University Hospital of Leuven



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.